1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,143 | 0,167 | 10:22 | |
| 0,146 | 0,166 | 27.03. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BRII BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 19.03. | Brii Biosciences Limited: Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results | 114 | PR Newswire | Advancing HBV Functional Cure Toward Key Phase 2b Data Readouts
Increasing Discovery Efforts to Drive Long-term Value Creation
Strong Cash Position Supporting Strategic... ► Artikel lesen | |
| 19.03. | BRII-B (02137): NOTIFICATION OF 2025 PFIC STATUS | - | HKEx | ||
| 19.03. | BRII-B (02137): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 | - | HKEx | ||
| 09.03. | BRII-B (02137): DATE OF BOARD MEETING | 1 | HKEx | ||
| 10.11.25 | BRII-B (02137): VOLUNTARY ANNOUNCEMENT PRESENTS LATE-BREAKING DATA FROM ONGOING PHASE 2 ENSURE STUDY AT AASLD 2025 | 1 | HKEx | ||
| 07.11.25 | BRII-B (02137): VOLUNTARY ANNOUNCEMENT PUBLICATION OF PHASE 2 ENSURE STUDY RESULTS IN NATURE MEDICINE | - | HKEx | ||
| 31.10.25 | BRII-B (02137): GRANT OF SHARE OPTIONS | 1 | HKEx | ||
| 28.10.25 | BRII-B (02137): GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS | 1 | HKEx | ||
| 27.10.25 | BRII-B (02137): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 21.08.25 | Brii Biosciences Limited: Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results | 169 | PR Newswire | Multiple Ongoing Phase 2b Studies Advancing HBV Functional Cure Strategy
Greater China Partnership with Joincare to Accelerate Development of Critical Care Antibiotic... ► Artikel lesen | |
| 30.03.25 | Brii Biosciences Limited: Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification | 177 | PR Newswire | Preliminary data from Cohort 4 of the ENSURE study supports a novel enrichment strategy to utilize BRII-179 to identify patients who are immune responders and... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOGEN | 165,50 | -0,21 % | Alteogen Stock Up On Upto $579 Mln Deal With Biogen For Hybrozyme-Based Subcutaneous Biologics | WESTON (dpa-AFX) - Shares of Alteogen Inc. (196170.KQ) gained around 6 percent on Thursday's trading in South Korea after the biopharma company announced that it has entered into an exclusive... ► Artikel lesen | |
| ILLUMINA | 102,14 | -5,44 % | Argus hebt Illumina-Kursziel wegen neuer Produkte auf 145 US-Dollar an | ||
| NANOREPRO | 1,415 | 0,00 % | NanoRepro: Strukturelle Stärkung im Kerngeschäft | Nach Darstellung der Analysten Matthias Greiffenberger und Cosmin Filker von GBC hat die NanoRepro AG in den ersten sechs Monaten des Geschäftsjahres 2025 (per 30.6.) den Umsatz deutlich um rund 37... ► Artikel lesen | |
| BRAIN BIOTECH | 2,370 | -5,20 % | EQS-News: BRAIN Biotech AG: BRAIN Biotech erhält bedeutendes Patent für seine CRISPR-BMC Genome-Editing-Technologie | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Patent
BRAIN Biotech erhält bedeutendes Patent für seine CRISPR-BMC Genome-Editing-Technologie
23.03.2026 / 11:05 CET/CEST
Für... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,334 | -3,47 % | BioNxt tritt in die Kommerzialisierungsphase ein - mit globalem Patentschutz und US-Fast-Track-Strategie für seine sublinguale Wirkstoffplattform | VANCOUVER, BC / ACCESS Newswire /
24. März 2026 / BioNxt Solutions Inc. ("BioNxt" oder das "Unternehmen") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), ein innovatives
Biowissenschaftsunternehmen, das... ► Artikel lesen | |
| INFLARX | 0,824 | +3,65 % | InflaRx N.V.: InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones | Promising Phase 2a data announced for izicopan, underscoring its potential as a meaningfully differentiated, effective and safe oral inhibitor of C5aRSubstantial progress made toward Phase 2b readiness... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,345 | -4,96 % | Defence Therapeutics Inc: Defence extends warrant expiry, lowers exercise price | ||
| TREVENA | 4,000 | +1.983 % | TREVENA INC - 8-K, Current Report | ||
| BURCON NUTRASCIENCE | 1,220 | +3,39 % | Burcon NutraScience Corporation: Burcon Closes Second Tranche of Non-Brokered Private Placement of Convertible Debentures of up to $6.9 Million | Vancouver, British Columbia--(Newsfile Corp. - February 27, 2026) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based... ► Artikel lesen | |
| TME PHARMA | 0,063 | 0,00 % | TME Pharma NV: TME Pharma extends financial runway to over 12 months | TME Pharma extends financial runway to over 12 months Berlin, Germany, March 9, 2025, 08.00am CET - TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing... ► Artikel lesen | |
| CYTODYN | 0,230 | 0,00 % | CytoDyn Inc. - 8-K, Current Report | ||
| IMMUNIC | 1,090 | -1,45 % | Immunic garners new Buy at Guggenheim on lead asset | ||
| IOVANCE BIOTHERAPEUTICS | 3,199 | -1,80 % | Iovance Biotherapeutics, Inc.: Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas | 50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,245 | -2,35 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement | King of Prussia, Pennsylvania--(Newsfile Corp. - March 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 12,215 | +0,78 % | Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results | SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics... ► Artikel lesen |
Das Unternehmen BRII BIOSCIENCES LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,004 (+2,80 %) liegt der Kurs bei 0,147 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BRII BIOSCIENCES LTD finden Sie auf Wallstreet Online.